QSAM Biosciences
Manufacturing · Texas, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
9442 N Capital of Texas Hwy Ste 500 1, A...Phone Number
(512) 343-4558Website
www.qsambio.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About QSAM Biosciences
QSAM Biosciences, Inc. is developing next-generation nuclear medicines for the treatment of cancer and related diseases. QSAM is based in Austin, Texas.Explore more
QSAM Biosciences Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is QSAM Biosciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once QSAM Biosciences has new funding data
Website visits: Recent activity has been detected on your website
Check out if QSAM Biosciences is spiking on competitors!
Check if QSAM Biosciences has recently received funding, and reach out quickly before it becomes old news!
Click to see if QSAM Biosciences had a recent Job posting/layoffs
QSAM Biosciences, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when QSAM Biosciences launches new products
Congratulate Masked Content for being promoted to Masked Content at QSAM Biosciences
Earning: See what the market has to say on QSAM Biosciences recently announced quarterly report
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to QSAM Biosciences
Compare insights from companies similar to QSAM Biosciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
<$5M
11-50
Private
$555M
2018
PR
Paul ReinfeldsSenior Vice President - Legal Affairs and General Counsel
Company Profile Activity
Activity Insights
QSAM Biosciences is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
QSAM Biosciences is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about QSAM Biosciences.
QSAM Biosciences financials insights
Gather financial insights about QSAM Biosciences, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Series B
$2.5M
QSAM Biosciences Tech Stack
A closer look at the technologies used by QSAM Biosciences
Most Recent Scoops
Mergers & Acquisitions (M&A)
Project
Funding
Funding
Funding
QSAM Biosciences News & Media
Telix Signs Agreement to Acquire QSAM Biosciences and Its Bone Cancer Targeting Platform
MELBOURNE, Australia , Feb. 8, 2024 /PRNewswire/ --.Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has entered into an agreement to acquire QSAM Biosciences, Inc. (U.S. OTC: QSAM) and its lead investigational drug Samarium-153-DOTMP (153Sm-DOTMP). QSAM is a United States (U.S.) based company developing therapeutic radiopharmaceuticals for primary and metastatic bone cancer. 153Sm-DOTMP is a novel kit-based bone-seeking targeted radiopharmaceutical candidate thatQSAM Biosciences Signs Definitive Agreement to be Acquired by Telix Pharmaceuticals
Austin, TX, Feb. 07, 2024 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM) (“QSAM or the “Company”) has signed a definitive Agreement and Plan of Merger (the “Agreement”) providing for the acquisition of the Company by Telix Pharmaceuticals Limited (ASX: TLX) (“Telix”).QSAM Biosciences Signs Term Sheet to be Acquired by Telix Pharmaceuticals; Receives $2 Million Pre-Closing Collaboration and Option Fee
Austin, TX, Nov. 14, 2023 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing therapeutic radiopharmaceuticals for the treatment of primary and secondary bone cancer and related conditions, has signed a non-binding term sheet (the “Term Sheet”) with Telix Pharmaceuticals (US) Inc., a subsidiary of Telix Pharmaceuticals Limited (ASX: TLX) (collectively, “Telix”) providing material terms for the acquisition of the Company by Telix by means of a merger (the “Acquisition”).Telix Announces Proposed Acquisition of QSAM Biosciences and Its Lead Therapy Candidate, CycloSam®
MELBOURNE, Australia, Nov. 13, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has signed a conditional Term Sheet to acquire QSAM Biosciences, Inc. (QSAM) and its lead asset, CycloSam® (Samarium-153-DOTMP). QSAM is a United States (U.S....
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding QSAM Biosciences
Sign Up For FreeTo access detailed company insights
QSAM Biosciences, Inc. is developing next-generation nuclear medicines for the treatment of cancer and related diseases. QSAM is based in Austin, Texas.... Read More
